Advertisement

Arrhythmogenic Right Ventricular Cardiomyopathy: Usefulness of Imaging in Prognostic Stratification and Choice of Treatment

  • Francesca BrunEmail author
  • Concetta Di Nora
  • Massimo Zecchin
  • Bruno Pinamonti
  • Gianfranco Sinagra
Chapter

Abstract

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disease characterized by myocyte loss and fibrofatty tissue replacement. It primary affects the RV, but it may involve the left ventricle (LV) and lead to biventricular heart failure (HF), life-threatening ventricular arrhythmias, and sudden death (SD). Implantable cardioverter defibrillators (ICD) are increasingly used in patients with ARVC who have survived SD (secondary prevention). However, few data are available to help identifying ARVC patients in whom prophylactic implantation of an ICD is truly warranted. Several risk factors have a proven clinical utility. All data reported may be useful in risk stratification and may help in deciding the correct clinical management of ARVC patients. Conclusive data on the prognostic value of each factor are still lacking.

Keywords

Sudden Death Ventricular Tachycardia Implantable Cardioverter Defibrillator Arrhythmogenic Right Ventricular Cardiomyopathy Nonsustained Ventricular Tachycardia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Clip 18.1

(MOV 816 kb)

Clip 18.2

(MOV 819 kb)

References

  1. 1.
    Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y (1982) Right ventricular dysplasia: a report of 24 adult cases. Circulation 65(2):384–398PubMedCrossRefGoogle Scholar
  2. 2.
    Hauer RN, Aliot E, Block M, Capucci A, Luderitz B, Santini M, Vardas PE (2001) Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur Heart J 22(13):1074–1081. doi: 10.1053/euhj.2001.2584 PubMedCrossRefGoogle Scholar
  3. 3.
    Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Riegel B, Tarkington LG, Yancy CW (2008) ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117(21):e350–e408. doi: 10.1161/CIRCUALTIONAHA.108.189742 PubMedCrossRefGoogle Scholar
  4. 4.
    Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48(5):e247–e346. doi: 10.1016/j.jacc.2006.07.010 PubMedCrossRefGoogle Scholar
  5. 5.
    Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Riegel B, Tarkington LG, Yancy CW (2008) ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51(21):e1–e62. doi: 10.1016/j.jacc.2008.02.032 PubMedCrossRefGoogle Scholar
  6. 6.
    Schinkel AF (2013) Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol 6(3):562–568. doi: 10.1161/CIRCEP.113.000392 PubMedCrossRefGoogle Scholar
  7. 7.
    Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F (2006) Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 114(25):2766–2772. doi: 10.1161/CIRCULATIONAHA.106.642892 PubMedCrossRefGoogle Scholar
  8. 8.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341(25):1882–1890. doi: 10.1056/NEJM199912163412503 PubMedCrossRefGoogle Scholar
  9. 9.
    Pires LA, Hafley GE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Buxton AE (2002) Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction. J Cardiovasc Electrophysiol 13(8):757–763PubMedCrossRefGoogle Scholar
  10. 10.
    Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ (2007) Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115(13):1710–1720. doi: 10.1161/CIRCULATIONAHA.106.660241 PubMedCrossRefGoogle Scholar
  11. 11.
    Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ (2004) Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J Med 117(9):685–695. doi: 10.1016/j.amjmed.2004.04.028 PubMedCrossRefGoogle Scholar
  12. 12.
    Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd, Buja G, Thiene G (2003) Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108(25):3084–3091. doi: 10.1161/01.CIR.0000103130.33451.D2 PubMedCrossRefGoogle Scholar
  13. 13.
    Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, Thierfelder L, Stuckless SN, Dicks EL, McKenna WJ, Connors SP (2005) The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 45(3):400–408. doi: 10.1016/j.jacc.2004.08.068 PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR, Calkins H (2004) Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 43(10):1843–1852. doi: 10.1016/j.jacc.2004.01.030 PubMedCrossRefGoogle Scholar
  15. 15.
    Tavernier R, Gevaert S, De Sutter J, De Clercq A, Rottiers H, Jordaens L, Fonteyne W (2001) Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart 85(1):53–56PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TD, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Bocker D (2004) Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 109(12):1503–1508. doi: 10.1161/01.CIR.0000121738.88273.43 PubMedCrossRefGoogle Scholar
  17. 17.
    Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP (2001) Task Force on Sudden cardiac Death of the European Society of Cardiology. Eur Heart J 22(16):1374–1450. doi: 10.1053/euhj.2001.2824 PubMedCrossRefGoogle Scholar
  18. 18.
    Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G (2004) Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 110(14):1879–1884. doi: 10.1161/01.CIR.0000143375.93288.82 PubMedCrossRefGoogle Scholar
  19. 19.
    Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, Kupprion C, Ramadanova K, Thierfelder L, McKenna W, Gallagher B, Morris-Larkin L, Bassett AS, Parfrey PS, Young TL (2008) Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82(4):809–821. doi: 10.1016/j.ajhg.2008.01.010 PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gatzoulis K, Protonotarios N, Anastasakis A, Tsatsopoulou A, Vlasseros J, Gialafos J, Toutouzas P (2000) Implantable defibrillator therapy in Naxos disease. Pacing Clin Electrophysiol 23(7):1176–1178PubMedCrossRefGoogle Scholar
  21. 21.
    Wichter T, Breithardt G (2005) Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: a role for genotyping in decision-making? J Am Coll Cardiol 45(3):409–411. doi: 10.1016/j.jacc.2004.11.009 PubMedCrossRefGoogle Scholar
  22. 22.
    Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, Migliore F, Marra MP, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori D, Iliceto S, Thiene G, Basso C, Corrado D (2013) Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 6(6):533–542. doi: 10.1161/CIRCGENETICS.113.000288 PubMedCrossRefGoogle Scholar
  23. 23.
    Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivotto I (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55(14):1444–1453. doi: 10.1016/j.jacc.2009.11.062 PubMedCrossRefGoogle Scholar
  24. 24.
    Bauce B, Frigo G, Marcus FI, Basso C, Rampazzo A, Maddalena F, Corrado D, Winnicki M, Daliento L, Rigato I, Steriotis A, Mazzotti E, Thiene G, Nava A (2008) Comparison of clinical features of arrhythmogenic right ventricular cardiomyopathy in men versus women. Am J Cardiol 102(9):1252–1257. doi: 10.1016/j.amjcard.2008.06.054 PubMedCrossRefGoogle Scholar
  25. 25.
    Daliento L, Turrini P, Nava A, Rizzoli G, Angelini A, Buja G, Scognamiglio R, Thiene G (1995) Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: similarities and differences. J Am Coll Cardiol 25(3):655–664. doi: 10.1016/0735-1097(94)00433-Q PubMedCrossRefGoogle Scholar
  26. 26.
    McRae AT 3rd, Chung MK, Asher CR (2001) Arrhythmogenic right ventricular cardiomyopathy: a cause of sudden death in young people. Cleve Clin J Med 68(5):459–467PubMedCrossRefGoogle Scholar
  27. 27.
    Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ (1989) Long-term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J 10(Suppl D):68–73PubMedCrossRefGoogle Scholar
  28. 28.
    Turrini P, Corrado D, Basso C, Nava A, Bauce B, Thiene G (2001) Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation 103(25):3075–3080PubMedCrossRefGoogle Scholar
  29. 29.
    Silvano M, Corrado D, Kobe J, Monnig G, Basso C, Thiene G, Eckardt L (2013) Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Herzschrittmacherther Elektrophysiol 24(4):202–208. doi: 10.1007/s00399-013-0291-5 PubMedCrossRefGoogle Scholar
  30. 30.
    Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H (2011) Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 58(14):1485–1496. doi: 10.1016/j.jacc.2011.06.043 PubMedCrossRefGoogle Scholar
  31. 31.
    Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA 3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI (2010) Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122(12):1144–1152. doi: 10.1161/CIRCULATIONAHA.109.913871 PubMedCrossRefGoogle Scholar
  32. 32.
    Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121(13):1533–1541. doi: 10.1161/CIRCULATIONAHA.108.840827 PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Pinamonti B, Sinagra G, Salvi A, Di Lenarda A, Morgera T, Silvestri F, Bussani R, Camerini F (1992) Left ventricular involvement in right ventricular dysplasia. Am Heart J 123(3):711–724PubMedCrossRefGoogle Scholar
  34. 34.
    Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, Di Lenarda A, Morgera T, Mestroni L, Sinagra G (2011) Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J 32(9):1105–1113. doi: 10.1093/eurheartj/ehr040 PubMedCrossRefGoogle Scholar
  35. 35.
    Lemola K, Brunckhorst C, Helfenstein U, Oechslin E, Jenni R, Duru F (2005) Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. Heart 91(9):1167–1172. doi: 10.1136/hrt.2004.038620 PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Deac M, Alpendurada F, Fanaie F, Vimal R, Carpenter JP, Dawson A, Miller C, Roussin I, di Pietro E, Ismail TF, Roughton M, Wong J, Dawson D, Till JA, Sheppard MN, Mohiaddin RH, Kilner PJ, Pennell DJ, Prasad SK (2013) Prognostic value of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol 168(4):3514–3521. doi: 10.1016/j.ijcard.2013.04.208 PubMedCrossRefGoogle Scholar
  37. 37.
    Santangeli P, Pieroni M, Dello Russo A, Casella M, Pelargonio G, Macchione A, Camporeale A, Smaldone C, Bartoletti S, Di Biase L, Bellocci F, Natale A (2010) Noninvasive diagnosis of electroanatomic abnormalities in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 3(6):632–638. doi: 10.1161/CIRCEP.110.958116 PubMedCrossRefGoogle Scholar
  38. 38.
    Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G (1992) Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86(1):29–37PubMedCrossRefGoogle Scholar
  39. 39.
    Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, Estes NA 3rd, Marcus F, Scheinman MM (2009) Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 54(7):609–615. doi: 10.1016/j.jacc.2009.04.052 PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Pinamonti B, Di Lenarda A, Sinagra G, Silvestri F, Bussani R, Camerini F (1995) Long-term evolution of right ventricular dysplasia-cardiomyopathy. The Heart Muscle Disease Study Group. Am Heart J 129(2):412–415PubMedCrossRefGoogle Scholar
  41. 41.
    Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE (2009) Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 120(5):366–375. doi: 10.1161/CIRCULATIONAHA.108.834903 PubMedCrossRefGoogle Scholar
  42. 42.
    Corrado D, Basso C, Nava A, Thiene G (2001) Arrhythmogenic right ventricular cardiomyopathy: current diagnostic and management strategies. Cardiol Rev 9(5):259–265PubMedCrossRefGoogle Scholar
  43. 43.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240–e319. doi: 10.1161/CIR.0b013e31829e8776 PubMedCrossRefGoogle Scholar
  44. 44.
    Lacroix D, Lions C, Klug D, Prat A (2005) Arrhythmogenic right ventricular dysplasia: catheter ablation, MRI, and heart transplantation. J Cardiovasc Electrophysiol 16(2):235–236. doi: 10.1046/j.1540-8167.2005.40495.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Francesca Brun
    • 1
    Email author
  • Concetta Di Nora
    • 1
  • Massimo Zecchin
    • 1
  • Bruno Pinamonti
    • 1
  • Gianfranco Sinagra
    • 1
  1. 1.Department of CardiologyUniversity Hospital of TriesteTriesteItaly

Personalised recommendations